The radiomics subcommittee of the RWG is exploring the potential role of radiomics in enhancing response assessment in clinical trials of investigational oncology agents.  This subcommittee is composed of oncologists with an interest in clinical trials and drug development, radiologists with expertise in response assessment and radiomics, data scientists, and biostatisticians. Potential applications of radiomics in response assessment include further refining the definition of “stable disease” and for distinguishing between pseudoprogression and true disease progression with immunooncology agents. The initial steps of this committee are to investigate potential signals and signatures that appear to be consistent findings across multiple publications and tumour types, and which could be suggested for inclusion as exploratory endpoints in prospective clinical trials.